DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Buy the dips in quality names with earnings visibility : Hemang Jani
8/05/2025
Putin's order for three-day truce with Ukraine enters force
8/05/2025
BSE issues cybersecurity advisory amid rising Pakistan-linked threats to Indian BFSI Sector
8/05/2025
RBI bumper Rs 3.5 trillion payout to help offset weak revenues, analysts say
8/05/2025
